CD38 Monoclonal Antibody (14.27), eFluor™ 660, eBioscience™, Invitrogen™

Description

• The MAb 14.27 reacts with rat CD38, also known as ADP-ribosyl cyclase
• CD38 is a type II transmembrane glycoprotein that is an ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic adenosine diphosphate ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP)
• cADPR and NAADP are secondary messengers involved in calcium mobilization
• CD38 can also act as a receptor for CD31 or agonist monoclonal antibodies
• CD38 is expressed by leukocytes, early hematopoietic precursor cells, epithelial cells, astrocytes, some muscle cells, kidney cells, and thyroid cells
• CD38 plays a role in the production of pro-inflammatory cytokines, proliferation, cell activation, cell migration, cell adhesion, and protection from apoptosis
• CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells
• CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor
• Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e
• identification of myelomas), and as a marker for activated B and T cells
• CD38 participates in cell adhesion, signal transduction and calcium signaling
• Further, CD38 is expressed at high levels in the pancreas, liver, kidney, malignant lymphoma and neuroblastoma
• Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter's Syndrome.